| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SJA6017 targets the calcium-dependent cysteine proteases µ-calpain and m-calpain. It is a cell-permeable peptide aldehyde that acts as a reversible inhibitor by binding to the active site cysteine residue. It inhibits calpain-1 with an IC50 of 7.5 nM and calpain-2 with an IC50 of 78 nM. It also inhibits cathepsins B and L, which are lysosomal cysteine proteases. By inhibiting calpains, it prevents the proteolysis of substrates involved in signaling, cytoskeletal remodeling, and apoptosis. This makes it a key tool for studying calpain biology.
|
|---|---|
| ln Vitro |
In vitro, SJA6017 is a potent calpain inhibitor. It inhibits purified m-calpain with an IC50 of 80 nM. It is cell-permeable, allowing intracellular activity. The compound's activity is assessed by measuring calpain activity in cell lysates or purified enzyme preparations using fluorogenic substrates. It is used to study the role of calpains in various cellular processes, including apoptosis, cell migration, and neurotoxicity. It has been suggested for use in cataract research due to its ability to inhibit calpain-mediated lens protein degradation.
|
| ln Vivo |
In vivo, SJA6017 is used to study the role of calpains in disease models. By inhibiting calpain activity, it can protect against tissue damage in models of ischemia, neurodegeneration, and muscle dystrophy. Its cell-permeability makes it suitable for in vivo applications. However, comprehensive in vivo efficacy data are limited, and further studies are needed to evaluate its therapeutic potential. It is primarily a research tool for validating calpain as a therapeutic target.
|
| Enzyme Assay |
The in vitro enzyme assay for SJA6017 involves measuring calpain activity using a fluorogenic peptide substrate, such as Suc-LLVY-AMC. Purified calpain-1 or calpain-2 is pre-incubated with varying concentrations of SJA6017 (0.1 nM–10 µM) in the presence of calcium. The reaction is initiated by adding substrate, and the fluorescence (excitation 360 nm, emission 460 nm) is monitored over time. IC50 values are calculated from dose-response curves. Selectivity against cathepsins can be assessed using similar assays with cathepsin-specific substrates.
|
| Cell Assay |
In vitro cellular assays for SJA6017 use various cell lines, such as neurons, myocytes, or cancer cells. Cells are treated with the compound at concentrations of 0.1–10 µM for 1–24 hours. Calpain activity is measured in cell lysates using fluorogenic substrates. Cell viability is assessed using MTT or LDH release assays. Apoptosis is evaluated by caspase-3/7 activity and Annexin V staining. The compound's effect on calpain substrates (e.g., spectrin breakdown products) is analyzed by Western blot. These assays help characterize its cellular mechanism.
|
| Animal Protocol |
In vivo animal studies for SJA6017 typically involve models of ischemia (e.g., middle cerebral artery occlusion), neurodegeneration (e.g., MPTP model), or muscle dystrophy. The compound is administered via intraperitoneal or intravenous injection at doses of 1–30 mg/kg. Endpoints include infarct volume, neurological scores, muscle histology, and calpain activity in tissues. Pharmacodynamic studies measure inhibition of calpain-mediated proteolysis. However, published in vivo data are limited, and the compound is mainly used in vitro.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of SJA6017 are not extensively reported. It has a molecular weight of 356.45 and a molecular formula of C17H25FN2O4S. It is soluble in DMSO and has good cell permeability. For storage, it should be kept at -20°C as a powder. In solvent, store at -80°C. Its peptide aldehyde nature may confer moderate stability in biological fluids. Further PK studies (half-life, bioavailability, tissue distribution) are needed for in vivo applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for SJA6017 are limited. As a calpain inhibitor, it may affect normal cellular functions, but its selectivity and reversible nature may reduce off-target toxicity. It is for research use only and not for human therapeutic applications. Standard safety precautions should be followed. For detailed toxicity, consult safety data sheets. High doses may cause cytotoxicity in some cell types, so appropriate concentrations must be determined empirically.
|
| References | |
| Additional Infomation |
SJA6017 (Calpain Inhibitor VI) is a cell-permeable peptide aldehyde calpain inhibitor with CAS 190274-53-4, formula C17H25FN2O4S, MW 356.45. It inhibits calpain-1 (IC50 7.5 nM), calpain-2 (78 nM), cathepsin B (15 nM), and cathepsin L (1.6 nM). It is used in research on calpain-mediated processes, including neurodegeneration, ischemia, and cataract. It is not FDA-approved and is strictly for research purposes only.
|
| Molecular Formula |
C17H25FN2O4S
|
|---|---|
| Molecular Weight |
372.4554
|
| Exact Mass |
372.151
|
| CAS # |
190274-53-4
|
| PubChem CID |
9885817
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.512
|
| LogP |
3.21
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
25
|
| Complexity |
537
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=CC(NC(C(NS(C1C=CC(F)=CC=1)(=O)=O)C(C)C)=O)CC(C)C
|
| InChi Key |
WSJWUIDLGZAXID-HOCLYGCPSA-N
|
| InChi Code |
InChI=1S/C17H25FN2O4S/c1-11(2)9-14(10-21)19-17(22)16(12(3)4)20-25(23,24)15-7-5-13(18)6-8-15/h5-8,10-12,14,16,20H,9H2,1-4H3,(H,19,22)/t14-,16-/m0/s1
|
| Chemical Name |
(2S)-2-[(4-fluorophenyl)sulfonylamino]-3-methyl-N-[(2S)-4-methyl-1-oxopentan-2-yl]butanamide
|
| Synonyms |
Calpain-In-4; Calpain Inhibitor 4; Calpain Inhibitor VI
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6849 mL | 13.4243 mL | 26.8485 mL | |
| 5 mM | 0.5370 mL | 2.6849 mL | 5.3697 mL | |
| 10 mM | 0.2685 mL | 1.3424 mL | 2.6849 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
